Treatment-resistant depression in late life

CNS Spectrums

Volumn 7, Issue 10, 2002, Pages 733-738

  Flint, Alastair J ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BUSPIRONE; LIOTHYRONINE; LITHIUM CARBONATE; MIRTAZAPINE; NORTRIPTYLINE; OLANZAPINE; PINDOLOL; PSYCHOSTIMULANT AGENT; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AGED; AGING; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; REMISSION; REVIEW;

EID: 0037785251     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900008725     Document Type: Review

References (53)

1. Flint AJ. Choosing appropriate antidepressant therapy in the elderly: a risk-benefit assessment of available agents. Drugs Aging. 1998;13:269-280.
2. Georgotas A, McCue RE, Hapworth W, et al. Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly. Biol Psychiatry. 1986;21:1155-1166
3. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62
4. Doraiswamy PM, Khan ZM, Donahue RM, Richard NE. Quality of life in geriatric depression. A comparison of remitters, partial responders, and nonresponders. Am J Geriatr Psychiatry. 2001;9:423-428
5. Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med. 1995;25:1171-1180
6. Souery D, Amsterdam J, de Montigny C, et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol. 1999;9:83-91
7. Thase ME, Rush AJ, Kasper S, et al. Tricyclics and newer antidepressant medications: treatment options for treatment-resistant depressions. Depression. 1994/1995;2:152-168
8. Flint AJ, Eastwood MR. Frontal lobe syndrome and depression in old age. J Geriatr Psychiatry Neurol. 1988;1:53-55
9. Burke WJ, Roccaforte WH, Wengel SP, et al. Disagreement in the reporting of depressive symptoms between patients with dementia of the Alzheimer type and their collateral sources. Am J Geriatr Psychiatry. 1998;6:308-319
10. Brodaty H, Luscombe G, Parker G, et al. Increased rate of psychosis and psychomotor change in depression with age. Psychol Med. 1997; 27:1205-1213.
11. Parker G, Roy K, Hadzi-Pavlovic D, et al. Psychotic (delusional) depression: a meta-analysis of physical treatments. J Affect Disord. 1992;24:17-24.
12. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry. 2000;157(suppl 4):1-45.
13. Guscott R, Grof P. The clinical meaning of refractory depression: a review for the clinician. Am J Psychiatry. 1991;148:695-704.
14. Harvey AT, Preskorn SH. Mechanism of action of venlafaxine in normal male volunteers. Clin Pharmacol Ther. 1997;61:175.
15. Abdelmawla A, Langley RW, Szabadi E, et al. Comparison of venlafaxine, desipramine and paroxetine on the dorsal hand vein in man. J Psychopharmacol 1997;11(suppl 3):A28.
16. Quitkin FM. The importance of dosage in prescribing antidepressants. Br J Psychiatry. 1985;147:593-597
17. Flint AJ. Management of anxiety in late life. J Geriatr Psychiatry Neurol. 1998;11:194-200.
18. Lawrenson RA, Tyrer F, Newson RB, et al. The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared. J Affect Disord. 2000;59:149-157.
19. Demyttenaere K. Compliance during treatment with antidepressants. J Affect Disord. 1997;43:27-39.
20. Kornstein SG, Schneider RK. Clinical features of treatment-resistant depression. J Clin Psychiatry 2001;62(suppl 16):18-25.
21. Baldwin RC, Simpson S. Treatment resistant depression in the elderly: a review of its conceptualisation, management and relationship to organic brain disease. J Affect Disord. 1997;46:163-173.
22. Alexopoulos GS. The depression-executive dysfunction syndrome of late life. A specific target for D3 agonists? Am J Geriatr Psychiatry. 2001;9:22-29.
23. Reifler BV, Teri L, Raskind M, et al. Double-blind trial of imipramine in Alzheimer's disease patients with and without depression. Am J Psychiatry. 1989;146:45-49.
24. Petracca GM, Chemerinski E, Starkstein SE. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. Int Psychogeriatr. 2001;13:233-240.
25. Fava GA, Savron G, Grandi S, et al. Cognitive-behavioural management of drug-resistant major depressive disorder. J Clin Psychiatry. 1997;58:278-282.
26. Fava M. Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry. 2001;62(suppl 18):4-11.
27. Bauer M, Doffmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol. 1999;19:427-434.
28. Joffe RT, Singer W, Levitt AJ, et al. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry. 1993;50:387-393.
29. Gitlin MJ, Weiner H, Fairbanks L, et al. Failure of T3 to potentiate tricyclic antidepressant response. J Affect Disord. 1987;13:267-272.
30. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001;158:131-134.
31. Landen M, Bjorling G, Agren H, et al. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry. 1998;59:664-668.
32. Appelberg BG, Syvalahti EK, Koskinen TE, et al. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry. 2001;62:448-452.
33. Moreno FA, Gelenberg AJ, Bachar K, et al. Pindolol augmentation of treatment-resistant depressed patients. J Clin Psychiatry. 1997;58:437-439.
34. Perez V, Soler J, Puigdemont D, Alvarez E, et al. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Arch Gen Psychiatry. 1999;56:375-379
35. Fava M, Rosenbaum JF, McGrath PJ, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind controlled study. Am J Psychiatry. 1994;151:1372-1374.
36. Katona CLE, Abou-Saleh MT, Harrison DA, et al. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry. 1995;166:80-86.
37. Flint AJ. Augmentation strategies in geriatric depression. Int J Geriatr Psychiatry. 1995;10:137-146.
38. Bauer M, Bschor T, Kunz D, et al. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry. 2000;157:1429-1435.
39. Fahy S, Lawlor BA. Discontinuation of lithium augmentation in an elderly cohort. Int J Geriatr Psychiatry. 2001;16:1004-1009.
40. Posternak MA, Zimmerman M. Switching versus augmentation: a prospective, naturalistic comparison in depressed, treatment-resistant patients. J Clin Psychiatry. 2001;62:135-143.
41. Flint AJ, Rifat SL. The effect of sequential antidepressant treatment on geriatric depression. J Affect Disord. 1996;36:95-105.
42. Georgotas A, Friedman E, McCarthy M, et al. Resistant geriatric depressions and therapeutic response to monoamine oxidase inhibitors. Biol Psychiatry. 1983;18:195-205.
43. Joffe RT, Levitt AJ, Sokolov ST, Young LT. Response to an open trial of a second SSRI in major depression. J Clin Psychiatry. 1996;57:114-115.
44. Thase ME, Blomgren SL, Birkett MA, et al. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry. 1997;58:16-21.
45. Prudic J, Haskett RF, Mulsant B, et al. Resistance to antidepressant medications and short-term clinical response to ECT. Am J Psychiatry. 1996;153:985-992.
46. Sackeim HA, Prudic J, Devanand DP, et al. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch Gen Psychiatry. 2000;57:425-434.
47. Flint AJ, Rifat SL. The treatment of psychotic depression in later life: a comparison of pharmacotherapy and ECT. Int J Geriat Psychiatry. 1998;13:23-28.
48. Pascual-Leone A, Rubio B, Pallardo F, et al. Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Lancet. 1996;348:233-237.
49. Loo C, Mitchell P, Sachdev P, et al. Double-blind controlled investigation of transcranial magnetic stimulation for the treatment of resistant major depression. Am J Psychiatry. 1999;156:946-948.
50. Padberg F, Zwanzger P, Thoma H, et al. Repetitive transcranial magnetic stimulation (rTMS) in pharmacotherapy-refractory major depression: comparative study of fast, slow and sham rTMS. Psychiatr Res. 1999;88:163-171.
51. Sackeim HA, Rush AJ, George MS, et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology. 2001;25:713-728.
52. Little JT, Reynolds CF, Dew MA, et al. How common is resistance to treatment in recurrent, nonpsychotic geriatric depression? Am J Psychiatry. 1998;155:1035-1038.
53. Keller MB, Boland RJ. Implications of failing to achieve successful longterm maintenance treatment of recurrent unipolar major depression. Biol Psychiatry. 1998;44:348-360.